VBLT - Vascular Biogenics trades lower after an update on ovarian cancer study

koto_feja/E+ via Getty Images Vascular Biogenics (VBLT), operating as VBL Therapeutics has paused the recruitment of new patients in the U.S. for its ongoing OVAL Phase 3 study designed to investigate ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. Vascular Biogenics  has lost ~9.7% in the pre-market. The OVAL study has enrolled nearly 75% of the planned 400-patients to date. The FDA has informed the company that the regulatory clearance of new VB-111 batches for use in the U.S. is pending the completion of a technical review. “Until new batches are cleared, the Company anticipates a temporary shortage of study drug supply for the U.S.” VBL Therapeutics said in the statement adding that the treatment will continue as usual for all currently enrolled U.S. patients. Early this month, VBL Therapeutics announced an amendment to the study adding a second, separate primary endpoint to measure the progression-free survival ((PFS)).

For further details see:

Vascular Biogenics trades lower after an update on ovarian cancer study